Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study

Front Oncol. 2022 Jun 7:12:889996. doi: 10.3389/fonc.2022.889996. eCollection 2022.

Authors

Affiliations

¹ Lowe Center for Thoracic Oncology and Dana-Farber Cancer Institute, Boston, MA, United States.
² Bristol Myers Squibb, Princeton, NJ, United States.
³ Acetylon Pharmaceuticals, Inc, Boston, MA, United States.
⁴ Dana-Farber Cancer Institute and Belfer Center for Applied Cancer Science, Boston, MA, United States.
⁵ Virginia Cancer Specialists (VCS) Research Institute, Fairfax, VA, United States.

Abstract

[This corrects the article DOI: 10.3389/fonc.2021.696512.].

Keywords: ACY-241; HDAC6; citarinostat; nivolumab; non-small cell lung cancer.

Copyright © 2022 Awad, Le Bruchec, Lu, Ye, Miller, Lizotte, Cavanaugh, Rode, Dumitru and Spira.

Publication types

Published Erratum